Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301916 | 1.00 | METTL3 (0.45) | METTL3ADORA1ADRB1ADRB3MAOA | |
| SCHEMBL1301419 | 0.92 | METTL3 (0.46) | METTL3APEX1KMT2AMEN1MAPT | |
| SCHEMBL1301424 | 0.92 | METTL3 (0.46) | METTL3APEX1KMT2AMEN1MAPT | |
| SCHEMBL1300908 | 0.87 | METTL3 (0.42) | METTL3KMT2AGSK3BMAPT | |
| SCHEMBL1300902 | 0.87 | METTL3 (0.42) | METTL3KMT2AGSK3BMAPT | |
| SCHEMBL1300646 | 0.85 | METTL3 (0.44) | METTL3KMT2AMEN1GSK3B | |
| SCHEMBL1300641 | 0.85 | METTL3 (0.44) | METTL3KMT2AMEN1GSK3B | |
| SCHEMBL1300784 | 0.85 | METTL3 (0.43) | METTL3MAPT | |
| SCHEMBL1300778 | 0.85 | METTL3 (0.43) | METTL3MAPT | |
| SCHEMBL1302316 | 0.84 | METTL3 (0.46) | METTL3ADORA1KMT2AGSK3BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885ADORA1 4124/4885ADRB1 4448/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885ADORA1 4124/4885ADRB1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.